Meeting Banner
Abstract #3141

Assessment of Neoadjuvant Chemotherapeutic Response of Bladder Cancer by Dynamic Contrast-Enhanced MRI at 3T

Huyen Thanh Nguyen1,2, Guang Jia1, Zarine K. Shah1, Kamal S. Pohar3, Amir Mortazavi4, Daniel Clark1, Mitva Patel1, Debra L. Zynger5, Michael V. Knopp1,2

1Wright Center of Innovation in Biomedical Imaging & Department of Radiology, the Ohio State University, Columbus, OH, United States; 2Biophysics Program, the Ohio State University, Columbus, OH, United States; 3Department of Urology, the Ohio State University, Columbus, OH, United States; 4Department of Internal Medicine, the Ohio State University, Columbus, OH, United States; 5Department of Pathology, the Ohio State University, Columbus, OH, United States


The aim of this on-going study is to evaluate the usefulness of DCE-MRI in the assessment of neoadjuvant chemotherapeutic response of bladder cancer. A linear two-compartment pharmacokinetic model was used to calculate pharmacokinetic parameters and their maps. The results showed that DCE-MRI was able to increase significantly the accuracy of the assessment from 67% to 92%, reveal the changes in perfusion characteristics of bladder tumor due to the chemotherapy, and map out the responsive and non-responsive regions of bladder tumor. These promising results indicated that DCE-MRI is a reliable and powerful tool to assess and predict the neoadjuvant chemotherapeutic response of bladder cancer.